BIO.B News Alert Bio Rad Labs Cl B (BIO.B) 120.51 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 7:36 PM

Bio Rad Labs Cl B (BIO. 120.51 $BIO.B

Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay
Marketwired - Wed Nov 19, 3:45PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius(TM) HIV 1/2 Supplemental Assay (test).
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad posts 3Q profit
Automated Insights - Tue Nov 04, 5:36PM CST
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO) on Tuesday reported net income of $11.5 million, or 39 cents per share, in its third quarter.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Reports Third-Quarter 2014 Financial Results
Marketwired - Tue Nov 04, 3:28PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2014.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad paying $55M to resolve US bribery claims
By MARCY GORDON - AP - Mon Nov 03, 4:00PM CST
WASHINGTON (AP) — Bio-Rad Laboratories Inc. has agreed to pay about $55 million to resolve U.S. authorities' allegations that it failed to prevent bribery of officials in Russia, Thailand and Vietnam and falsified records to hide the payments.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government
Marketwired - Mon Nov 03, 1:16PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced the full resolution of previously disclosed investigations by the U.S. Department of Justice (DOJ) and Securities and Exchange Commission (SEC) into past violations of the Foreign Corrupt Practices Act (FCPA) that occurred from 2005 to 2010 related to Thailand, Vietnam, and Russia.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014
Marketwired - Wed Oct 08, 5:06PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2014 on Tuesday, November 4, 2014, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments
Marketwire - Wed Oct 01, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostics products, today announced the recent appointment of Mr. John Goetz as Chief Operating Officer. In his new role Mr. Goetz is responsible for all operating functions of the company on a global basis, including the Clinical Diagnostics and Life Science segments as well as global sales.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Laboratories (BIO. Downgraded From Buy to Hold
at The Street - Tue Sep 30, 8:00AM CDT
Bio-Rad Laboratories (BIO. has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
BIO.B: 120.51 (unch)

Bio-Rad Reports Second-Quarter 2014 Financial Results
Marketwire - Tue Aug 05, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2014.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Laboratories appoints Joel McComb to its board
M2 - Mon Jul 28, 6:47AM CDT
Life science company Bio-Rad Laboratories (NYSE:BIO) (NYSE:BIO. disclosed on Friday the election of Joel McComb to its board of directors.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Announces the Appointment of New Board Member
Marketwire - Fri Jul 25, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostics products, announced today that Joel McComb has been appointed to its Board of Directors.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad to Report Second-Quarter 2014 Financial Results Tuesday, August 5, 2014
Marketwire - Mon Jul 07, 4:31PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the second quarter 2014 on Tuesday, August 5, 2014, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Launches Vitamin D Kit for Its BioPlex 2200 System
Marketwire - Mon Jun 23, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , today announced the launch of the BioPlex(R) 2200 25-OH Vitamin D kit for use outside the U.S. on the company's BioPlex(R) 2200 system. The assay offers a fully-automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad unveils fifth generation fully-automated HIV screening test
M2 - Wed Jun 18, 6:06AM CDT
Life science company Bio-Rad Laboratories (NYSE:BIO) (NYSE:BIO. revealed on Tuesday the availability of its fifth generation HIV test, the BioPlex 2200 HIV Ag-Ab kit.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Bio-Rad Launches the First Fully-Automated 5th Generation HIV Test
Marketwire - Wed Jun 18, 1:34AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of its BioPlex(R) 2200 HIV Ag-Ab kit, the company's 5th generation HIV test for markets outside the U.S.
BIO: 120.32 (-0.04), BIO.B: 120.51 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPlat Gears Up for Q3 2026 Earnings Call

NextPlat's Upcoming Financial Revelation November is shaping up to be a month of revelations for NextPlat Corp (NASDAQ:NXPL) as they prepare to spill the beans on their third-quarter 2026 financials. The number crunching wraps up at 8:30 a.m. Eastern on November 12, when the execs will host an investor conference call. The Details of the Big Day Coming to you live from...

South Park Exhibition: A Sneak Peek Behind the Scenes

An Unconventional Legacy: South Park’s Journey There's a new kind of 'heritage' on display at the Colorado History Museum that's bound to shake a few eyebrows in December 2026. More than just cutouts and characters, South Park: Handmade in Colorado delves into the crazy, outrageous journey of Trey Parker and Matt Stone's brainchild from its humble beginnings to a...

Cavli's Latest Innovations Shine at electronica 2026

Cavli Wireless: Paving the Path for Smarter IoT There's a storm brewing in Munich at electronica 2026, and Cavli Wireless is the name spurred across tech-savvy lips. With their latest revelation—the P16QS LTE Cat 1bis module and Cortex AI—the firm’s tossing bold challenges at the IoT and AI landscape. It's a gutsy move, cementing their role as a frontier pusher in a...

Elanco Surges with Solid Q3, Raises 2026 Forecast

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Faith Leaders Reject Dominion-NextEra $67B Merger

Voices Raised Against a Corporate Giant Today, outside the drab halls of the Virginia State Corporation Commission (SCC), a group of faith leaders drew a line in the sand against a looming energy giant. The $67 billion move to merge Dominion Energy with NextEra Energy ignited their rallying cry. Phooey to sacrificing community well-being for corporate greed, they shouted....

Pangaea's Q3 2026: Record TCE Rates and Profits

Unpacking Pangaea's Stellar Q3 Performance Ah, the shipping industry—an ocean of numbers too vast for many, but Pangaea Logistics Solutions Ltd. (NASDAQ: PANL) has shown it knows how to chart a course through complex waters. The company announced mighty fine results for the third quarter of 2026, and folks, if you're looking for a cup of optimism in the logistics...

Golden 1 Credit Union Earns TIME's Top Company Honor

A Credit Union Shines in the Limelight Sitting in the honoree section isn't something credit unions are commonly known for, but Sacramento's very own Golden 1 Credit Union just barged into the room with a big win. TIME's inaugural list of America's Best Companies has rolled Golden 1 into the spotlight, solidifying its role not just as a financial leader but as a community...

Used Truck Inventory Shrinks as Auction Values Rise

October's Tailspin in Used Truck Inventory If you've been around the block in the trucking industry, the latest from Sandhills Global might just knock your socks off. Their October rundown is out, and it's looking bleak for anyone trying to grab a used truck or trailer at a bargain. We're seeing a real crunch in inventory, and that’s an understatement. Navigating a...

Tata Power Faces Enforcement Order for $650M Debt

Tata's Troubles Escalate Grab a cup of coffee, folks, because this is one rollercoaster of a story that every investor needs to have on their radar. We're talking about Singapore courts coming down on Tata Power like a freight train, with enforcement orders that feel like a page out of a high-stakes drama. The Gavel Drops: What's Happening? The court in Singapore has...

Ravens & MedStar Host Cancer Patients' Tailgate Bash

If you thought a hospital could never host a touchdown of a tailgate, think again. The Baltimore Ravens and MedStar Health joined forces to throw the second annual Ravens Crucial Catch Tailgate Experience. This ain't your average pre-game party, folks—it's a blowout right in the hospital for cancer patients and their families, serving up a hefty dose of fun, food, and,...